Kidney disease in lupus is not always 'lupus nephritis' by Anders, H.J. (Hans-Joachim) & Weening, J.J. (Jan)
In the previous issue of Arthritis Research & Th erapy, 
Song and colleagues [1] discussed specifi c kidney abnor-
malities in patients with lupus erythematosus (LE). LE 
can manifest as cutaneous LE or as a systemic disorder 
(systemic lupus erythematosus, or SLE) [2]. In patients 
with LE, renal abnormalities, such as elevated serum 
creatinine levels or urinary abnormalities, require further 
diagnostic work-up because they may indicate renal 
involvement in SLE or an unrelated form of renal disease 
[3]. Furthermore, renal symptoms may indicate fl ares of 
disease activity in patients with established lupus 
nephritis but may also refl ect renal injury due to con-
comitant toxicity or infectious disease. How should lupus 
nephritis be defi ned? Th e current classifi cation of the 
International Society of Nephrology/Renal Pathology 
Society (ISN/RPS) is based on the phenotype of immune 
complex glomerulonephritis that depends on the pre-
dominant site of immune complex deposition within the 
glomerulus and on diff erent stages of acute (and 
poten tially reversible) injury and chronic (and potentially 
irreversible) scarring [4]. Th e article on ISN/RPS classifi -
cation of lupus nephritis [4] emphasizes the importance 
of including all other forms of kidney injury, separate 
from immune complex-mediated glomerulonephritis, in 
the diagnostic evaluation of the renal biopsy in SLE, 
including thrombotic microangiopathy (TMA). Th e 
article advocates that ‘the extent, severity, and type of 
tubulointerstitial injury (tubular atrophy, interstitial 
fi brosis, and chronic lesions) and vascular disease (vas-
cular deposits, thrombi, vasculitis, sclerosis) should also 
be documented and graded (mild, moderate, severe) in 
the diagnostic line’ [4].
Song and colleagues [1] presented a detailed histo-
patho logical analysis of a series of 148 patients with 
biopsy-proven lupus nephritis, focusing on the preva-
lence of TMA. Th e authors defi ned TMA by light micros-
copy as interlobular artery, arteriole, and glomerular 
capillary lesions, including endothelial swelling, lumen 
narrowing or obliteration, and thrombi formation. 
Electron microscopic TMA criteria are swelling of glo-
merular endothelial cells, detachment from glomerular 
basement membrane, and widening of the subendothelial 
space. Fibrin staining identifi es acute microthrombi, 
where as mucoid changes and onionskin lesions of 
arterioles were considered chronic. Th e authors found 
such TMA lesions in 36 out of the 148 patients with 
lupus nephritis [1]. In some of these cases, TMA was a 
manifestation of associated systemic autoimmune states 
such as the anti-phospholipid antibody syndrome, sclero-
derma, or thrombotic thrombocytopenic purpura, which 
have specifi c diagnostic criteria and are not included as a 
specifi c category in the current ISN/RPS classifi cation of 
lupus nephritis [4].
In the majority of cases, TMA was associated with 
immune complex-mediated forms of lupus nephritis. 
According to the authors, such cases can be missed easily 
unless fi brin immunostaining is performed. TMA results 
from severe injury to the vascular endothelium, which 
Song and colleagues [1] found to be associated with 
poorer renal outcomes as compared with patients with 
non-TMA lupus nephritis. As such, reporting TMA in 
the renal biopsy and defi ning the ISN/RPS class are 
important, even though the management implications 
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In lupus erythematosus, elevated serum creatinine 
levels and urinary abnormalities implicate a kidney 
disorder, which may not always be lupus nephritis as 
defi ned by the current classifi cation of the International 
Society of Nephrology/Renal Pathology Society. The 
signs of renal dysfunction may be caused by lupus-
unrelated renal injury such as drug toxicity or infection 
or by lupus-associated mechanisms that are not part 
of the classifi cation, such as minimal change nephrotic 
syndrome or thrombotic microangiopathy. The latter 
seems to complicate lupus nephritis more frequently 
than previously thought. An unbiased assessment of 
kidney disease in lupus requires a kidney (re-)biopsy to 
defi ne the appropriate management.
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remain unclear unless a causative disorder such as the 
anti-phospholipid antibody syndrome (anticoagulation), 
overlap syndrome with scleroderma (angiotensin inhibi-
tion), or thrombotic thrombocytopenic purpura (plasma 
exchange) can be identifi ed.
Th e report by Song and colleagues reminds us that, in 
LE, elevated serum creatinine levels or urinary abnor-
malities (or both) may not always represent immune 
complex glomerulonephritis (that is, ‘lupus nephritis’). In 
addition, patients with SLE can develop other kidney 
disorders that may be related or unrelated to SLE and 
SLE management (Table 1) [3].
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Table 1. Types of kidney disease in patients with systemic 
lupus erythematosus
Immune complex glomerulonephritis (‘lupus nephritis’)
Immune complex tubulointersitial nephritis
Minimal change nephrotic syndrome
Thrombotic microangiopathy
Infectious ascending tubulointerstitial disease
Opportunistic renal infections
Renal drug-induced toxicity
Renal injury due to concomitant disease (for example, hypertension and 
diabetes mellitus)
Amyloidosis
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